A Modular, Phase I, Open-label, Multicenter Study to Eval...

Inclusion Criteria:

Age:

Type of Participant and Disease Characteristics:

For NDMM participants:

Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prior anti- myeloma therapy (no more than 2 cycles of induction therapy before enrollment are acceptable)
For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and a maximum of 6 cycles of induction therapy completed prior to screening
Classified as high-risk MM

For Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants:

Have received and failed 1 or 2 lines of anti-myeloma therapy
Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as part of their previous therapy
Have documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria within 1 year of starting treatment, or on or within 6 months of completing treatment of the subject's last line of anti-myeloma therapy, or have confirmed progressive disease within 6 months prior to screening and who are subsequently determined to be refractory or non-responsive to their most recent anti-myeloma treatment regimen

General Exclusion Criteria:

Have received prior treatment with CAR T therapy directed at any target
Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
Active or history of plasma cell leukemia at the time of screening
Seropositive for human immunodeficiency virus (HIV)
Active Hepatitis B infection
Active Hepatitis C infection
Serious underlying medical condition

Clinical Trial Details